Triple negative breast cancer Trials in Lleida, Spain
Conditions / Triple negative breast cancer / Lleida, Spain
Triple negative breast cancer is a medical condition with active clinical research programs worldwide.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | RECRUITING | — |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02032277 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | COMPLETED | PHASE3 |
| NCT04408118 | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC | COMPLETED | PHASE2 |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | TERMINATED | PHASE2 |
| NCT05520723 | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED | COMPLETED | PHASE2 |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | COMPLETED | PHASE1 |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | RECRUITING | PHASE2 |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | TERMINATED | PHASE2 |